Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 25, 2023: PDS0101 (SC) / Pembrolizumab (IV) / Head and Neck Cancer / PDS Biotechnology: Encouraging data from Phase 2 VERSATILE-002 study PDS Biotechnology reported encouraging data […]
Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 24, 2023: Sitravatinib (IV) / Nivolumab (Opdivo) (IV) / NSCLC / Mirati Therapeutics: Phase 3 SAPPHIRE study did not meet the primary endpoint of overall survival The […]
Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 23, 2023: Pembrolizumab (IV) / Lenvatinib (IV) / Endometrial Cancer / Merck / Eisai: Received a NICE recommendation NICE recommends Pembrolizumab + Lenvatinib for Endometrial Cancer in […]
Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 23, 2023: Toripalimab (IV) / Advanced Triple-Negative Breast Cancer / Junshi Bio: China NMPA accepted supplemental new drug application (sNDA) This application was based on the findings […]
Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 22, 2023: LUMISIGHT / Breast cancer / Lumicell: FDA granted a priority review The FDA granted priority review to a new drug application seeking approval of the […]
Weekly Digest – 20-26 May 2023 Weekly Digest – 20-26 May 2023 May 22, 2023: IDE397 / AMG 193 / Solid tumors / Ideaya Biosciences: IND approved for Phase 1/2 study The FDA cleared an IND for Phase 1/2 trial […]
